Literature DB >> 15908956

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.

Anders Castor1, Lars Nilsson, Ingbritt Astrand-Grundström, Miranda Buitenhuis, Carole Ramirez, Kristina Anderson, Bodil Strömbeck, Stanislaw Garwicz, Albert N Békássy, Kjeld Schmiegelow, Birgitte Lausen, Peter Hokland, Sören Lehmann, Gunnar Juliusson, Bertil Johansson, Sten Eirik W Jacobsen.   

Abstract

The cellular targets of primary mutations and malignant transformation remain elusive in most cancers. Here, we show that clinically and genetically different subtypes of acute lymphoblastic leukemia (ALL) originate and transform at distinct stages of hematopoietic development. Primary ETV6-RUNX1 (also known as TEL-AML1) fusions and subsequent leukemic transformations were targeted to committed B-cell progenitors. Major breakpoint BCR-ABL1 fusions (encoding P210 BCR-ABL1) originated in hematopoietic stem cells (HSCs), whereas minor BCR-ABL1 fusions (encoding P190 BCR-ABL1) had a B-cell progenitor origin, suggesting that P190 and P210 BCR-ABL1 ALLs represent largely distinct tumor biological and clinical entities. The transformed leukemia-initiating stem cells in both P190 and P210 BCR-ABL1 ALLs had, as in ETV6-RUNX1 ALLs, a committed B progenitor phenotype. In all patients, normal and leukemic repopulating stem cells could successfully be separated prospectively, and notably, the size of the normal HSC compartment in ETV6-RUNX1 and P190 BCR-ABL1 ALLs was found to be unaffected by the expansive leukemic stem cell population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908956     DOI: 10.1038/nm1253

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  99 in total

Review 1.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

3.  Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Kenneth Dorshkind
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

4.  Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Authors:  Richard T Williams; Willem den Besten; Charles J Sherr
Journal:  Genes Dev       Date:  2007-08-30       Impact factor: 11.361

5.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

Review 6.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

Review 9.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

10.  Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.

Authors:  Kerrie Wilson; Marian Case; Lynne Minto; Simon Bailey; Nick Bown; Jenny Jesson; Sarah Lawson; Josef Vormoor; Julie Irving
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.